Vitality Biopharma Inc (OTCMKTS:VBIO) Hints at Cannabinoid Breakthrough


The last time we talked about Vitality Biopharma Inc (OTCMKTS:VBIO) here on Street Register several months ago, the company had just obtained positive results demonstrating antimicrobial activity of cannabinoids and filed for patent protection on the use of cannabinoid compounds for the treatment of microbes including Clostridium difficile and other “superbug” pathogens.

Clostridium difficile, is at the top of the CDC’s (Center for Disease Control) list of pathogens classified as an urgent threat to human health. The CDC reported in 2015 that it infected almost 500,000 Americans and was directly responsible for 15,000 deaths. Vitality successfully demonstrated antimicrobial reactivity of a cannabinoid against C. diff, and is currently conducting follow-on studies designed to enable pharmaceutical use of their targeted cannabinoid prodrugs for this application.

That was in May, and while the ensuing few months included fundraising and presenting its data at several high profile conferences, this week has been the first time since that we’ve received new information regarding the company’s studies.

Vitality Biopharma Inc (OTCMKTS:VBIO) has announced the achievement of a biosynthesis breakthrough. The company has developed a proprietary biosynthesis technology that can modify cannabinoids in order to create pharmaceutical prodrugs that have no psychoactivity and that are able to provide targeted disease treatment. This process involves small molecule glycosylation, where sugar molecules are attached to cannabinoids, creating new compounds known as cannabinoid glycosides, or cannabosides.

Small molecule glycosylation is well known within the pharmaceutical industry to modify and in many ways improve drug properties for cannabinoids and many other compounds, but traditionally the chemical synthesis of glycosides has been very challenging. Over the past several years, Vitality has developed efficient methods for biosynthetic production of glycosides, rather than chemical synthesis, and is now reporting a marked improvement to these biosynthetic production methods.

The Company was able to recently improve the yields of its primary enzymatic biocatalyst more than 15-fold, and over the course of the past year to reduce more than half the amount of time necessary for its production in large fermentation batches. This enzyme is a key component of Vitality’s proprietary biosynthesis methods and it was originally derived from the Stevia plant. In late 2015, the Company discovered that that the enzyme was far more promiscuous and more broadly useful than researchers within the stevia industry had ever appreciated before. This discovery led to an international patent filing covering a new class of cannabinoid pharmaceutical prodrugs.

“With our cannabinoid pharmaceutical program, we are quickly moving from ‘bench to bedside,’ so it’s important to recognize technical milestones like this one that have enabled and sped our progress,” said Robert Brooke, CEO of Vitality Biopharma. “Our team first pioneered enzymatic biosynthesis methods for cannabosides and now has made their production far more efficient and scalable.” (Source: Marketwired)

We talk about the cannabis industry primarily pertaining to companies capitalizing on relaxed legislation and the recreational markets. Even the medical arena where marijuana is prescribed for various ailments. But VBIO is doing heavy medical research into the compounds contained in cannabis, putting it on a whole other level from the companies we usually discuss. Now also happens to be a good time for us to have revisited the stock, as it has just begun to gain some traction off of recently established 9-month lows. We’ll stay up on any further developments with VBIO and pass them along to you! Stay locked on and be sure you’re signed up for our 100% free smallcap newsletter. It’s as easy as that! Simply submit your primary active email address in the box below. Subscribe now!

Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in VBIO stock, short or long.